Serina Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
SER$1.430.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three months endedJune 30, | Six months endedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| REVENUES | ||||
| Grant revenues | $— | $130 | $— | $130 |
| Total revenues | — | 130 | — | 130 |
| OPERATING EXPENSES | ||||
| Research and development | 3,816 | 3,152 | 7,015 | 6,103 |
| General and administrative | 2,968 | 2,543 | 6,049 | 5,450 |
| Total operating expenses | 6,784 | 5,695 | 13,064 | 11,553 |
| Loss from operations | (6,784) | (5,565) | (13,064) | (11,423) |
| OTHER INCOME (EXPENSE), NET | ||||
| Interest expense | (203) | (9) | (392) | (9) |
| Change in fair value of warrants | 50 | (956) | 154 | 33 |
| Change in fair value of tranche liability | 347 | — | 1,377 | — |
| Loss on extinguishment of financial commitment assets and contingent warrants, net | — | — | (1,616) | — |
| Other income, net | 234 | 68 | 287 | 115 |
| Total other income (expense), net | 428 | (897) | (190) | 139 |
| NET LOSS | (6,356) | (6,462) | $(13,254) | $(11,284) |
| Less: Net loss attributable to noncontrolling interest | — | (14) | — | (23) |
| NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. | $(6,356) | $(6,448) | $(13,254) | $(11,261) |
| NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDERS | $(8,932) | $(6,565) | $(15,867) | $(11,378) |
| NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDERS,BASIC AND DILUTED | $(0.55) | $(0.66) | $(1.11) | $(1.15) |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING,BASIC AND DILUTED | 16,385 | 10,004 | 14,232 | 9,883 |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
| Three months endedJune 30, | Six months endedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| NET LOSS | $(6,356) | $(6,462) | $(13,254) | $(11,284) |
| OTHER COMPREHENSIVE LOSS | ||||
| Foreign currency translation adjustment | 8 | — | 14 | — |
| COMPREHENSIVE LOSS | (6,348) | (6,462) | (13,240) | (11,284) |
| Less: Net loss attributable to noncontrolling interest | — | (14) | — | (23) |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. | $(6,348) | $(6,448) | $(13,240) | $(11,261) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.